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Abstract 
Background: The national Adverse Events Following Immunization (AEFI) surveillance system in 
China (CNAEFIS) has collected AEFI reports -including deaths -following all vaccines used in 
China since 2008.  
Aims: To review reports of AEFI-associated death cases from 2010 to 2015 to assess potential 
vaccine safety issues.  
Methods: Descriptive analysis of epidemiologic characteristic of AEFI-associated death cases and 
standard causality assessment for reported causes of deaths. To estimate the risk of death after 
vaccination, we used population data, administered doses and live births to calculate denominators. 
Results: During 2010-2015, 753 deaths were reported to CNAEFIS from mainland China. Highest 
numbers were reported in 2013 and 2014 when reporting peak of AEFI-associated deaths occurred 
after media reports concerning “death following Hepatitis B vaccination” in China. About 95% of 
deaths were in children <5 years of age and males accounted for 60%. Most common vaccines 
associated with reports of fatal AEFIs were vaccines in national immunization schedule. In causality 
assessment, 120 (16.0%) deaths were classified as vaccine-associated reactions such as anaphylactic 
reactions and disseminated BCG infections; 594 (78.9%) deaths were identified as coincidental 
events. The main causes of death were asphyxia, and Sudden Infant Death Syndrome. The overall 
estimated AEFI-associated death rates were: 0.26 per million vaccination doses administered and 
0.09 per million population. The neonatal AEFI death rate was 0.77 per million live births.  
Conclusions: These data provide reassuring information about the small risk of death following 
immunization. They also illustrate sensitivity of passive reporting to public information and that 
peaks in serious AEFI reports should be interpreted with caution. Continuous monitoring and 
scientific causality assessment for serious AEFIs, including AEFI-associated deaths is imperative to 
ensure public confidence in the immunization program. 
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1. Introduction 
China initiated the National Expanded Program on Immunization (EPI) in 1978 and expanded it to 
cover 14 types of vaccines in National Immunization Schedule in late 2007 [1]. As part of the EPI 
in China, about 22 vaccine doses are administered during the first year of life [2]. With its 1.3 billion 
inhabitants and over 17 million annual newborns, China is one of the largest market and 
manufacturer for vaccines in the world [3].  On average, more than 500 million vaccine doses are 
administered every year [2]. Deaths that occur after immunization, particularly neonatal or infant 
deaths frequently attract media attention and cause public concern. Recently, concerns were raised 
about adverse events following immunization (AEFI) and vaccine safety [4]. After media reports of 
deaths following hepatitis B vaccine (HepB) administration in Hunan province of China in 
December 2013, concerns about the vaccine safety increased among parents and the public [4]. 
However, vaccinations during childhood are common, and determining whether or not they are 
associated with pediatric deaths is difficult.  
All vaccines administered in mainland China are monitored and considered to be safe and effective 
by the National Regulatory Authority [3]. Since 2008, Chinese Center for Disease Control and 
Prevention (CCDC) has monitored AEFI reports, which are recorded using a passive AEFI 
nationwide surveillance program (Chinese AEFI Information System [CNAEFIS]) [5]. Since its 
implementation, the CNAEFIS has collected information on a large number of AEFI cases 
associated with vaccines used in China.  
To understand the epidemiological characteristics, causes of death, and risk of death following 
vaccination in China, we reviewed and analyzed reports of deaths after immunization from 2010 to 
2015. 
2. Materials and methods 
2.1 Data sources  
The CNAEFIS is a nationwide passive surveillance system for AEFI [2, 5]. In 2008, after 3 years 
of various pilot studies [6-7], the CNAEFIS became an online system covering all provinces. The 
AEFI surveillance of mass immunization campaigns, including the 2009 A(H1N1) influenza 
vaccine campaign during 2009–2010 influenza season [8] and measles vaccines campaign, which 
included more than 100 million children in 10 days in September 2010 [9] were covered by 
CNAEFIS, strengthening the reporting capacity. In June 2010, Chinese Ministry of Health and the 
Food and Drug Administration jointly issued a national AEFI guideline that made the CNAEFIS the 
sole and official surveillance system in mainland China [10]. 
According to the national AEFI guideline, an AEFI is defined as a reaction or an event after 
vaccination that is suspected to be related to vaccination. Healthcare facilities, vaccination units, 
local centers for disease control and prevention (CDCs), adverse drug reaction monitoring agencies, 
vaccine manufacturers, and their executive staff are responsible for reporting AEFIs. In addition, 
the public can notify any of these bodies. The data are collated by local county CDCs. These centers 
verify the AEFI Case Reporting information, which is then entered the CNAEFIS. Duplicate reports 
are detected and deleted by county-level, prefectural-level and provincial level CDCs. Once a case 
is reported in the CNAEFIS, it can be viewed online by CDCs, and adverse drug reaction monitoring 
agencies [10].  
2.2 Causality assessment 
According to national AEFI guidelines [10], all deaths reported in the CNAEFIS must be 
investigated. County-level CDCs commence an investigation by collecting relevant data and 
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completing the AEFI Case Investigation Form, which is entered in CNAEFIS. An ad hoc AEFI 
Investigation and Diagnosis Expert Committee is then established by the CDCs. The committee 
includes experts in clinical medicine, epidemiology, laboratory practices, pharmacy, vaccinology, 
vaccine regulation, and related fields, as needed. In cases of deaths, prefectural or provincial CDCs 
establish the AEFI Investigation and Diagnosis Expert Committee, which includes experts and 
committee members related to the case. This Committee then conducts the causality assessment 
[5,10]. 
After the causality assessment, the AEFI (including reports of deaths) is classified into one of the 
following categories [10]: 1) vaccine reactions or vaccine-related reactions, 2) vaccine quality 
reactions, 3) program errors or immunization errors, 4) coincidental events, or 5) psychogenic 
reactions or immunization anxiety-related reactions. 
2.3 Data collection 
Deaths which were suspected to be related to the vaccinations, with dates of death from 1st January 
2010 to 31st December 2015, were extracted from CNAEFIS and included in the study. Information 
collected included age and gender of the patients, vaccines received, results and conclusions of the 
causality assessments, time intervals from vaccinations to onset of symptoms, clinical diagnoses, 
and concurrent vaccines administered. 
2.4 Calculation of reporting rates  
We used the following denominators to estimate the risk of AEFI-associated deaths: 1) administered 
doses collected from vaccination clinics during the study period, 2) population data from the 
National Bureau of Statistics of the People’s Republic of China, and 3) neonatal death rates after 
vaccination. For denominator 1 and 2, the numerator was AEFI-associated deaths reported to 
CNAEFIS during the same period. The rates were calculated per million administered vaccination 
doses or per million population. For denominator 3, we used administered doses for first dose of 
HepB vaccine which administered within 24h after birth and vaccination coverage to estimate the 
number of live births. The numerator was cases who died within 28 days after birth.  
2.5 Statistical analysis 
All calculations were performed by using R software, version i386 3.2.3; the epitools package was 
used to calculate confidence intervals for Poisson rates. 
3. Results 
3.1 Characteristics of AEFI-associated deaths 
A total of 753 AEFI-associated deaths were reported during 2010–2015. AEFI-related deaths peaked 
in 2013–2014 (Fig. 1). The proportion of neonatal deaths varied from 5.0% (2010, 2011) to 16.5% 
(2013). In 2012–2014, the proportion exceeded 10.0%. All deaths were reported from locations 
within mainland of China.  
During the first quarter of the year (January to March), there were 249 (33.1%) AEFI-associated 
deaths, followed by 234 (31.1%) during the fourth quarter, 140 (18.6%) and 130 (17.3%) during the 
third and second quarters, respectively. Fifty-one AEFI-associated deaths were reported in 
December 2013, and 34 (66.7%) of these were related to HepB vaccine, administered alone or with 
other vaccines (Fig. 2). 
Of AEFI-associated death reports, 293 (38.9%) were females, 635 (84.3%) were aged <1 year, and 
82 (10.9%) cases were aged 1–4 years (Table 1). The median age in the group aged <1 year was 68 
days, and the median age in the group aged 1–4 years was 1 year old.  
Sixty-Nine different vaccines or vaccine combinations were associated with reported deaths. The 
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most common vaccines or vaccine combinations were 1) HepB (alone) (182, 24.2%), 2) Bacillus 
Calmette Guerin (BCG) and HepB (116, 15.4%), 3) oral poliomyelitis vaccine (OPV) and diphtheria, 
tetanus and acellular pertussis combined vaccine (DTaP) (84, 11.2%), 4) BCG (alone) (61, 8.1%), 
and 5) DTaP (alone) (31, 4.1%) (Table 2).   
3.2 Results of the causality assessments  
Autopsies were conducted in 257 (34.1%) cases. According to the causality assessment, 120 (15.9%) 
deaths were classified as vaccine reactions, 594 (78.9%) deaths were due to coincidental events, 38 
(5.1%) deaths were classified as indeterminate, and 1 (0.1%) death was due to an immunization 
error-related reaction. No deaths were classified as due to vaccine quality defect-related reactions 
or immunization anxiety-related reactions during the study period (Table 2) 
3.2.1 Vaccine-related reactions 
One hundred-twenty deaths were classified as vaccine-related reactions, with an estimated rate of 
0.04 per million doses, using the all vaccination doses as the denominator. Anaphylactic reactions 
accounted for 55 cases, in which 53 cases occurred within 1 day after vaccination. Anaphylactic 
reactions take 45.8% of vaccine-related reactions, with estimated rates of 0.02 per million 
vaccination doses. Nineteen vaccines or vaccine combinations were related to anaphylactic 
reactions. The average numbers of deaths per year due to anaphylactic reactions post-vaccination 
was about 9 (range: 6–13 cases). The most common vaccine and vaccine combinations associated 
with vaccine reactions were HepB (alone) (12 cases), OPV and DTaP (10 cases), BCG and HepB (9 
cases).  
There were 39 BCG-related deaths (estimated rate: 0.37 per million BCG vaccination doses). Thirty 
BCG-related deaths were classified as the result of disseminated BCG infections, and nine cases 
were due to BCG lymphadenitis or other infections (recurring). One death due to vaccine associated 
Vaccine-Associated Paralytic Poliomyelitis (VAPP) was reported. One case of hemorrhagic measles 
was reported in which the autopsy and laboratory findings confirmed that this was related to the 
vaccine virus.  
Thirteen deaths were attributed to neurological, illness, of which six cases were meningitis (aseptic 
or viral), four cases were acute disseminated encephalomyelitis, two cases were encephalopathy, 
and one case was epilepsy. Seven vaccines and vaccine combinations were administered in these 
cases, of which the rabies vaccine was the most common vaccine, accounting for five deaths. The 
average number of deaths per year was three, with a range of two to four in the study period. 
Nine deaths were confirmed as status thymicolymphaticus (STL) after autopsies. Other two cases 
were diagnosed as malaise and vomiting post vaccination, and both died of aspiration asphyxia. In 
all above 11 cases, vaccination was not the direct cause of death. However, in the causality 
assessment, the expert committee concluded that vaccination contributed to these deaths and 
classified the deaths as vaccine-related reactions. 
3.2.3 Immunization errors 
Only one death was classified as immunization error-related reaction. In this case, the baby had been 
diagnosed with severe malnutrition prior to immunization, and the immunization nurse had failed 
to perform a physical examination when the parents requested that the infant be vaccinated. The 
direct cause of death was severe malnutrition, respiratory failure, and cardiac failure, not vaccine 
related. 
3.2.4 Coincidental events 
After causality assessment, 594 deaths were classified as coincidental events. The most common 
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causes of death were asphyxia, sudden infant death syndrome (SIDS), pneumonia (neonatal and 
infant), congenital heart diseases, and vitamin K deficiency (which could lead to internal bleeding). 
In these cases, 577 (97.1%) deaths occurred within 15 days after vaccination. Sixty vaccines and 
vaccine combinations were administered, the most common were HepB (alone) (163 cases), BCG 
and HepB (92 cases), OPV and DTaP (65 cases), OPV (alone) (26 cases), and BCG (alone) (24 
cases). In 574 (96.6%) cases, the patients aged < 5 years.  
3.2.5 Indeterminate cause of death 
During 2010–2015, 38 deaths were classified as due to indeterminate causes. There was no clear 
clinical diagnosis in 25 (65.8%) cases, and for the rest cases there was insufficient evidence 
available to conduct the causality assessment. All 38 deaths occurred within one-week post-
vaccination, and 34 (89.5%) cases aged < 5 years.  
3.3 Risk estimation of AEFI-associated deaths 
Using all administered doses as the denominator, the average rate of AEFI-associated death was 
0.26 per million vaccination doses (range: 0.20-0.32) during the study years. Using population data 
as the denominator, the average rate was 0.09 per million population (range: 0.07-0.12) (Table 3). 
Neonatal deaths accounted for 10.4% (78 cases) of all reported AEFI-associated deaths. The highest 
rate of reported neonatal deaths after vaccination occurred in 2013 (1.48 per million live births) 
(Table 4). The rate of neonatal deaths after vaccination in 2010–2011 was significally different from 
2013–2014 (Table 4). During 2013–2014, 47 neonatal deaths were reported and 44 (93.6%) of those 
were related to HepB (with concurrent vaccines). In the causality assessment however, only one of 
the reported deaths was considered causally related to vaccination.  
During 2010-2015, we identified 182 reports of AEFI-associated deaths after vaccination with HepB 
was the only vaccine used. Of these, 13 were causally related to vaccination in the causality 
assessment. The annual numbers of causally related deaths during the period were 2,3,2,1,3,2, 
respectively.  
4. Discussion 
During six years of AEFI surveillance in mainland China, more than three quarters of reported 
AEFI-associated deaths were due to coincidental events, and only 16% could be attributed to 
vaccination by causality assessment. Most of those determined to be causally related to vaccination 
were related to anaphylactic reactions and disseminated BCG diseases. Although the reporting rates 
of neonatal deaths increased during 2013-2014, deaths that causally related to HepB were only 1-3 
cases during the study years.  
Overall, our study provides reassuring information about the small risk of deaths following 
immunization. Although 5% AEFI-associated deaths were indeterminate cause, the AEFI 
investigation and causality assessment process provided valuable information to evaluate vaccine 
safety in China. The reporting peak of AEFI-associated deaths in late 2013 to early 2014, illustrates 
the sensitivity of passive reporting of serious AEFI to public information and the caution that should 
be exercised in interpreting peaks in serious AEFI reporting. Our analysis also illustrates progress 
made with vaccine safety monitoring during recent years in China.  
Several limitations should be considered when interpreting the study findings. As CNAEFIS is a 
passive surveillance, it has inherent limitations, including reporting bias, and lack of control groups 
[11]. The limitation of denominator-based risk estimation includes different resources to identify 
the vaccine-administered doses and unknown background information, which make it difficult to 
compare the observed to the expected, as well as among different settings [12]. In our study, the 
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denominators used were estimated from different data resources and one should be cautious about 
comparing the estimated rates with immunization related death rates in other countries. In China, 
compensation is available for reactions determined to be vaccine-related. When the expert panel 
finds no other cause of death, it might be concluding that the vaccine or vaccination was a 
contributor to the death in the causality assessment. In such cases, the families of the deceased are 
eligible to apply for compensation. This policy might increase the number of reports of vaccine-
related reactions.  
Regarding the seasonal distribution of deaths during the study period, except for 2013, deaths were 
more common in winter than in summer months, consistent with findings of similar studies 
elsewhere [13]. The results showed that children aged <5 years accounted for 95% of AEFI-
associated death, which is consistent with Vaccine Adverse Event Reporting System (VAERS) data 
in the U.S. [14] and the National Immunization Schedule in China. There were also more male than 
female deaths. This finding is consistent with data reported in the All Cause of Death Surveillance 
System in China [15]. Of the AEFI-associated deaths, 78.9% were classified as coincidental events. 
The reported causes of death were consistent with common causes of mortality nationally [16,17]. 
According to the National Bureau of Statistics of the People’s Republic of China 
(http://data.stats.gov.cn/easyquery.htm?cn=C01), all-cause neonatal death rates during 2010-2014 
were 5.9–8.3‰. The estimated neonatal death rates in this study were lower than all-cause neonatal 
death rates in the general population, suggesting no association of vaccinations with an increased 
risk of death at the population level. 
Generally, parents have their children vaccinated when they are in relatively good health. In 
situations where the infant dies shortly after immunization, parents and even health providers may 
blame vaccine [13]. Although vaccines play a vital role in preventing diseases in children, vaccine 
hesitancy has become an issue in many counties, including China [18,19]. Events in December 2013 
in Hunan province of mainland China provide an example of how such concerns was arise [20]. 
Media reports of 17 infant deaths, including one case of anaphylactic shock following HepB 
vaccination, raised widespread public concern in China [3,19]. After investigation, The China Food 
and Drug Administration reported that the deaths were not related to the vaccine, but instead with a 
variety of problems, including severe pneumonia, suffocation, kidney failure, severe diarrhea and 
congenital heart disease [3,19,20,21]. In passive surveillance systems, the behavior of parents and 
vaccine providers behavior may influence the number of reports. This publicity may have increased 
public awareness and led to a tendency to report deaths after immunization during 2013-2014. Our 
analysis showed a reporting peak during 2013-2014, in which 94% of the neonatal deaths were 
reported to be related with HepB. However, vaccine reactions determined to be causally related to 
HepB were rare during the study years. Although the overall number of all AEFI reports in 
CNAEFIS increased from 2010 to 2015, the number of serious AEFIs (events causing a potential 
risk to the health/life of a recipient leading to prolonged hospitalization, disability/incapacity, 
congenital abnormalities/birth defects or death) has remained constant [9,22-25].  
Causality assessments in China are performed in accordance to WHO guidelines [10,26]. The 
documented causes of death that could possibly occur due to the inherent properties of a vaccine are 
limited and include anaphylaxis, viscerotrophic disease following yellow fever vaccine, 
disseminated attenuated live vaccine agent infection in severely immune-compromised individuals 
and death from intussusception following rotavirusvaccine [27]. In China, yellow fever vaccine is 
not recommended, and rotavirus vaccines differ from those used internationally. In our study, the 
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most common causes of vaccine-related reactions and deaths were anaphylaxis and disseminated 
BCG infections. BCG is recommended at birth, without screening to determine the status of the 
immune system at that time. In our study, several deaths were due to neurological diseases. There 
was no solid evidence that these neurological diseases were caused by the vaccines or vaccination, 
although some studies reported temporal associations of such diseases with various immunizations 
[28,29]. When no etiologic agent is identified, and the person was healthy prior to immunization, a 
suspicion may arise in the causality assessment that the vaccine contributed to the death. Several 
cases with STL was also assessed to be causally related to vaccination during surveillance. STL is 
associated with immune system dysfunction. As reported previously, mild immune stimulation, such 
as that produced by minor trauma or immunizations, could give rise to sudden death among 
individuals with STL [30]. The expert committee concluded that it triggered these deaths, even when 
neither the vaccine nor the vaccination was the direct cause. Case causality assessments are 
extremely difficult. Strengthening the capacity of AEFI investigation and causality assessment is 
very important in the field of vaccine safety surveillance and evaluation in China. In 2018, WHO 
issued revised classification for causality assessment [31] which could be adopted and modified for 
the Chinese setting in future. 
5. Conclusions 
Vaccines are among the safest medical products in use. However, parents will naturally become 
concerned when serious adverse events occur after vaccination, even though the event may only be 
temporally related to immunization [32]. A functional vaccine safety surveillance system and 
thorough AEFI investigation for causality assessment can provide valuable information for both 
national regulatory authorities and the public [27]. Our study showed that the risk of death following 
vaccination was extremely small and did not identify specific safety concerns with vaccines used in 
China. Because passive surveillance might be stimulated by media reports and public concerns, 
continuous monitoring and scientific causality assessment of serious AEFI reports, including AEFI-
associated deaths, is imperative to ensure public confidence in the immunization program.   
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Figure 1 Reports of AEFI-associated deaths by year, 2010-2015 
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Figure 2 Seasonal distribution of AEFI-associated deaths, 2010-2015 
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Table1 AEFI-associated deaths by year of death, age and gender, 2010-2015 
 
<1 1-4 5-9 10-17 18-64 ≥65 Total 
N Female % N Female % N Female % N Female % N Female % N Female % N Female % 
2010 84 44.05 20 50.00 3 0 2 50.00 9 44.44 1 0 119 43.70 
2011 90 44.44 8 37.50 1 0  
 
1 100 1 100 101 44.55 
2012 79 27.85 12 25.00 2 50.00  
 
1 0.00 1 0 95 27.37 
2013 139 36.69 13 38.46  
 
2 0 2 50.00 2 50.00 158 36.71 
2014 141 39.01 15 40.00 3 0  
 
 
 
1 100 160 38.75 
2015 102 42.16 14 42.86 1 100  
 
2 0.00 1 0 120 41.67 
Total 635 39.06 82 40.24 10 20.00 4 25.00 15 40.00 7 42.86 753 38.91 
 
  
Table 2 AEFI-associated deaths by vaccine and vaccine combination, and the 
causality assessment classification, 2010-2015 
Vaccines and vaccine 
combinations 
vaccine 
reaction 
immunization 
error 
coincident
al events indeterminate Total 
HepB 13  163 6 182 
BCG+HepB 16 1 92 7 116 
OPV+DTaP 13  65 6 84 
BCG 34  24 3 61 
DTaP 7  22 2 31 
OPV   26 1 27 
HepB+OPV 2  17  19 
RabV 7  8 3 18 
JE-L 4  12 1 17 
OPV+DTaP+Hib 1  12  13 
Other 59 vaccines and 
vaccine combinations 23  153 9 185 
Total 120 1 594 38 753 
 
  
Table 3 Estimated overall AEFI-associated death rates using different denominators, 
2010-2015 
Year 
No. of 
 deaths 
All 
 vaccination 
doses 
 (millions) 
Estimated rates by vaccination doses 
 
Total 
 population 
(millions) 
Estimated rates by total population 
Deaths rates 
(per million 
vaccination doses) 
95% CI 
Deaths rates 
(per million 
population) 
95% CI 
2010 119 427.88 0.28 0.23-0.33  1340.91 0.09 0.07-0.11 
2011 101 461.44 0.22 0.18-0.27  1347.35 0.07 0.06-0.09 
2012 95 478.97 0.20 0.16-0.24  1354.04 0.07 0.06-0.09 
2013 158 489.21 0.32 0.27-0.38  1360.72 0.12 0.10-0.14 
2014 160 495.74 0.32 0.27-0.38  1367.82 0.12 0.10-0.14 
2015 120 504.23 0.24 0.20-0.28  1374.62 0.09 0.07-0.10 
Total 753 2857.49 0.26 0.25-0.28  8145.46 0.09 0.09-0.10 
 
  
 
Table 4 Estimated neonatal deaths rates after vaccination, 2010-2015 
Year 
No of 
Neonatal 
death 
Vaccination 
doses of 1st dose 
of Heptitis B 
(million doses) 
Vaccination 
coverage % 
estimation of 
live birth 
(million live 
birth) 
 Neonatal 
death rates (per 
million birth) 
95% CI 
2010 6 17.16 99.81 17.19 0.35 0.13-0.76 
2011 5 17.5 99.86 17.53 0.29 0.09-0.67 
2012 10 18.68 99.87 18.71 0.53 0.26-0.98 
2013 26 17.48 99.77 17.52 1.48 0.97-2.17 
2014 21 15.18 99.84 15.2 1.38 0.86-2.11 
2015 10 15.75 99.87 15.77 0.63 0.30-1.17 
Total 78 101.75 - 101.91 0.77 0.61-0.96 
 
 
